CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Revenues:
Total revenues	$ 1,045,712	$ 1,023,825	$ 1,943,553	$ 1,925,808
Operating expenses:
Cost of product sales (excluding amortization of acquired developed technologies)	116,268	109,902	220,888	205,389
Selling, general and administrative	358,399	338,523	872,412	690,235
Research and development	189,972	220,734	370,624	443,581
Intangible asset amortization	162,103	155,223	316,551	310,953
Acquired in-process research and development	905,362	0	905,362	10,000
Total operating expenses	1,732,104	824,382	2,685,837	1,660,158
Income (loss) from operations	(686,392)	199,443	(742,284)	265,650
Interest expense, net	(47,363)	(62,023)	(101,069)	(128,139)
Foreign exchange gain (loss)	(1,799)	507	(2,012)	(1,186)
Income (loss) before income tax benefit and equity in loss of investees	(735,554)	137,927	(845,365)	136,325
Income tax benefit	(17,170)	(30,653)	(34,982)	(18,984)
Equity in loss of investees	86	12	628	1,359
Net income (loss)	$ (718,470)	$ 168,568	$ (811,011)	$ 153,950
Net income (loss) per ordinary share:
Basic (in dollars per share)	$ (11.74)	$ 2.68	$ (13.28)	$ 2.45
Diluted (in dollars per share)	$ (11.74)	$ 2.49	$ (13.28)	$ 2.35
Weighted-average ordinary shares used in per share calculations - basic (in shares)	61,194	62,882	61,087	62,710
Weighted-average ordinary shares used in per share calculations - diluted (in shares)	61,194	69,625	61,087	69,684
Product sales, net
Revenues:
Total revenues	$ 985,571	$ 964,144	$ 1,824,989	$ 1,806,246
Royalties and contract revenues
Revenues:
Total revenues	$ 60,141	$ 59,681	$ 118,564	$ 119,562